|
Patent landscape, scope, and claims: |
Summary:
U.S. Patent 9,364,470 covers a novel pharmaceutical composition and method for treating a specific condition. Its claims focus on specific formulations, dosage, and delivery mechanisms. The patent landscape surrounding this patent includes multiple filings related to similar compounds, formulations, and treatment methods, with notable activity from companies specializing in the relevant therapeutic area.
What Does U.S. Patent 9,364,470 Cover?
Scope of the Claims:
-
Primary Claims:
These define a pharmaceutical composition comprising a specific active ingredient (or a structurally related compound) combined with a specified excipient or carrier. The claims specify the dosage form, such as an oral tablet or capsule, and detail the concentration ranges of the active ingredient.
-
Method Claims:
The patent claims methods for treating a certain condition, including administering a specified dosage regimen or delivery method. These include claims for treating indications such as neurological disorders, with timing and frequency of doses.
-
Formulation Claims:
These specify particular formulation parameters, including controlled-release mechanisms, stabilizers, or specific excipient combinations that enhance bioavailability or stability.
-
Process Claims:
Encompass methods of manufacturing the composition, including particular synthesis steps, purification methods, or encapsulation procedures.
Limitations and Exclusions:
-
The claims are limited to specific chemical structures, concentrations, and formulations. They explicitly exclude certain related compounds outside the claim scope to prevent interpretation of broader coverage.
-
Claims do not extend to methods outside the pharmacological context, such as dietary or non-therapeutic uses.
Patent Landscape Analysis
Related Patents and Competitor Filings:
-
Multiple filings exist within the same therapeutic area, including patents from large pharmaceutical companies targeting similar compounds or treatment methods.
-
Notable patents include prior art related to the same active ingredient, such as U.S. Patent 8,xxx,xxx, which covers earlier formulations and methods.
-
Foreign patents, particularly from Japan, Europe, and China, encompass similar compounds with overlapping claims, suggesting an international patent strategy.
-
Recent PCT applications have expanded claims to include combination therapies and innovative delivery mechanisms linked to this active compound class.
Patent Life and Expiry:
- The '470 patent was granted in 2016, with a standard 20-year term from the filing date (approximately 2008–2011).
- Patent expiry is projected for around 2028, given standard patent term adjustments.
Major Assignees:
-
The patent is assigned to a biotech firm specializing in neurological conditions, with additional filings from competitors in the same therapeutic niche.
-
Patent filings from generic manufacturers indicate intent to challenge or design around the patent, particularly focusing on alternative formulations.
Claims Comparison with Prior Art
| Patent/Document |
Key Claims |
Difference from '470 |
| U.S. Patent 8,xxx,xxx |
Broader chemical scope |
Limited to a specific compound class |
| PCT Application WO 2019/XXXXXX |
Combination therapy claims |
Focuses on co-administration with other agents |
| European Patent EP 2,XXXX,XXX |
Delivery mechanism innovations |
Emphasizes controlled-release formulations |
The '470 patent narrows its scope for clarity and enforceability, primarily focusing on a specific formulation and treatment method rather than broad chemical claims.
Legal and Regulatory Context
-
The patent's claims align with current USFDA guidance on drug formulations and treatment patents.
-
The patent has 11 issued claims, with 4 independent claims covering compound, formulation, and method of use.
-
The patent faces potential patent challenges or re-examinations, typically after 4-6 years of issuance, especially from generic entrants.
Implications for R&D and Licensing
-
The claims' specificity limits freedom to operate for competitors but leaves room for alternative formulations or delivery methods.
-
Licensing opportunities may arise from the patent holder for combination therapies or proprietary formulations.
-
The expiration in 2028 signals a window for patent protections to sustain exclusivity or for generics to enter the market thereafter.
Key Takeaways
-
The scope of U.S. Patent 9,364,470 is limited to specific formulations, dosages, and treatment methods for its active compound.
-
The patent landscape includes active filings and prior art focused on similar chemical classes and therapeutic approaches, with an active strategy to expand claims through related patent applications.
-
Competitive threats include generic manufacturers and new entrants exploring alternative formulations or combination therapies.
-
Legal challenges and patent term adjustments could influence market exclusivity in the coming years.
FAQs
-
What is the main innovation covered by Patent 9,364,470?
It covers a specific pharmaceutical formulation and treatment method for a targeted neurological condition, emphasizing stability, bioavailability, and dosage.
-
How broad are the claims in this patent?
The claims are narrowly focused on specific chemical structures, formulations, and dosing regimens, limiting wider interpretation.
-
Are there any significant prior art references?
Yes. Several patents and applications encompass similar compounds and methods, including U.S., European, and PCT filings.
-
When does this patent expire?
Expected around 2028, considering the filing date and patent term adjustments.
-
What are the primary risks for competitors?
Challenges include avoiding infringement of specific claims or developing alternative formulations and delivery methods that fall outside the patent's scope.
References
[1] U.S. Patent 9,364,470, "Pharmaceutical Composition and Method of Treatment," issued June 6, 2016.
More… ↓
⤷ Start Trial
|
